Heart failure (HF) with preserved ejection fraction (HFpEF) is currently considered an epidemic, accounting for up to 50% of all HF cases, showing a consistent trend of increasing prevalence over the next years, with significant morbidity and mortality rates.
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Compared to HF with reduced ejection fraction, progress in the treatment of HF has been much less pronounced in patients with HFpEF, in which personalization of pharmacotherapy regimens remains poorly defined. 3 -5 Myocardial fibrosis contributes to ventricular stiffness and impaired relaxation in patients with HFpEF. 6 -8 Specifically, excessive myocardial collagen cross-linking, a process catalyzed by the enzyme lysyl oxidase which increases the insolubility, stiffness and resistance to degradation of the collagen fibre (mainly type I), 9 and increased deposition of collagen type I are related to elevated filling pressures in patients with HFpEF. 10 Therefore, the functional impact of myocardial fibrosis in HFpEF patients is not just a matter of quantity (i.e. severity of deposition) but also of quality (i.e. degree of cross-linking among collagen fibrils) of collagen type I fibres.
The carboxy-terminal propeptide of procollagen type I (PICP) is generated during the extracellular conversion of procollagen type I into collagen type I by the enzyme procollagen carboxy-terminal proteinase.
11 A net release from the heart into the circulation has been reported in HF, 12 suggesting a cardiac origin for systemic PICP in this syndrome. Serum PICP levels correlate with myocardial collagen and collagen type I deposition. 12, 13 On the other hand, as collagen cross-linking determines the resistance of the collagen fibre to matrix metalloproteinase (MMP) degradation, the higher the cross-linking of collagen type I fibres, the lower the cleavage of the carboxy-terminal telopeptide of collagen type I (CITP) by the enzyme MMP-1. Thus, serum CITP:MMP-1 ratio has been shown to be inversely correlated with myocardial collagen cross-linking.
14 Interestingly, the CITP:MMP-1 ratio is independently associated with the risk of HF hospitalization in HF patients.
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The Aldo-DHF study, a multicentre, prospective, randomized, double-blind, placebo-controlled trial performed in 422 ambulatory patients with HFpEF showed that 1-year treatment with spironolactone was associated with a reduction in left ventricular (LV) filling pressures, LV mass and circulating amino-terminal pro-brain natriuretic peptide (NT-proBNP) levels without changes in maximal exercise capacity. 15 It has been suggested that spironolactone-induced improvement of LV diastolic dysfunction (LVDD) may be related to its anti-fibrotic actions.
16 -18 However, it is unknown whether spironolactone is able to affect the degree of myocardial collagen type I content, stiffness and resistance to degradation in patients with HFpEF. In addition, it is not known whether these characteristics of the collagen fibre may impact on the spironolactone's capacity to improve LVDD in HFpEF patients. Therefore, the aim of the current analysis was two-fold: (i) to assess the impact of spironolactone treatment on biomarkers of myocardial fibrosis, not only in terms of collagen deposition (as assessed by serum PICP) but also in terms of collagen cross-linking (as assessed by serum levels of the CITP:MMP-1 ratio), and (ii) to investigate whether the characteristics of myocardial fibrosis at baseline interact with spironolactone effects on LVDD.
. 
Methods
Aldo-DHF was a prospective, randomized, placebo-controlled, double-blind multicentre study. The trial design and primary results of Aldo-DHF have been previously published. 15 Briefly, eligible patients were enrolled and randomized (1:1 ratio) to spironolactone 25 mg once daily or matching placebo and followed over 12 months. Patients with stable HFpEF defined as New York Heart Association (NYHA) class II or III HF symptoms, LV ejection fraction (LVEF) ≥50% at rest, echocardiographic evidence of grade ≥ I diastolic dysfunction or atrial fibrillation, and peak oxygen consumption ≤25 mL/kg/min were eligible for participation. Major exclusion criteria included: prior documented LVEF ≤40%, significant coronary artery disease, myocardial infarction or coronary artery bypass graft surgery within 3 months, definitive or probable pulmonary disease [vital capacity <80% or forced expiratory volume in 1 s (FEV 1 ) <80% or reference values on spirometry], body mass index ≥36 kg/m 2 , or serum creatinine >1.8 mg/dL. The study protocol was reviewed and approved by the institutional review board of each participating centre, and all patients provided written informed consent prior to enrolment. Aldo-DHF was conducted in accordance with national laws, guidelines for good clinical practice, and the Declaration of Helsinki.
Circulating biomarkers
Biomarker assessments were performed in the serum collected at baseline and at study end 12 months after randomization. Analysis of CITP was performed using an enzyme-linked immunosorbent assay (ELISA) developed by USCN Life Science (Houston, TX, USA). The inter-assay and intra-assay coefficients of variation were 10.5% and 11.6%, respectively. The lower limit of detection was 44.3 pg/mL. Total serum MMP-1 was measured by an ELISA method (GE Healthcare, Buckinghamshire, UK). The inter-assay and intra-assay coefficients of variation were 12.4% and 7.0%, respectively. The lower limit of detection was 1.7 ng/mL. CITP and MMP-1 were expressed in molarity and the CITP:MMP-1 ratio was calculated in each patient as previously reported. 14 Serum PICP was measured using the EIA MicroVue CICP (Quidel Corporation, San Diego, CA, USA). The inter-assay and intra-assay coefficients of variation were 12.0% and 8.1%, respectively. The lower limit of detection was 0.2 ng/mL.
Statistical analysis
The study population was categorized into tertiles of serum CITP:MMP-1 ratio and PICP levels at baseline. Linear tests for trend were used to assess any tendency across the different subgroups. The distributions of all analysed biomarkers were normalized by a logarithmic transformation.
Associations between variables at baseline or between changes in variables over 12 months after treatment were assessed using a bivariate correlation (model 1), and were correlated as partial correlation coefficients corrected for sex and age only (model 2), and as partial correlation coefficients corrected for sex, age, atrial fibrillation, mean arterial pressure, estimated glomerular filtration rate, haemoglobin, and NT-proBNP (model 3). 19 The Benjamini and Hochberg multiple test correction (false discovery rate of 10%) was applied.
Testing for interaction between the effect of treatment (spironolactone or placebo) on LVDD and non-invasively assessed myocardial fibrosis was conducted in patients categorized into tertiles according to serum CITP:MMP-1 ratio or PICP levels by analysis of covariance with the follow-up value of E:e' ratio as dependent variable, the baseline E:e' ratio as covariate, and treatment, subgroup variable, and their respective interaction terms as factor variables. Analyses over 12 months of follow-up to evaluate the effects of spironolactone therapy vs. placebo were performed by analysis of covariance, binary, or ordinal logistic regression with the follow-up value as dependent variable, treatment as a factor, and the baseline value as continuous or categorical covariate, as appropriate for quantitative, binary, or ordinal categorical variables, on each subgroup of patients. Between-group comparisons are presented as mean differences or odds ratios. Biomarkers were analysed on the logarithmic scale, and the results were transformed back by the exponential function, leading to a geometric mean instead of a mean difference. P-values for the interaction term of treatment with E:e' and PICP were calculated in each subgroup of patients according to tertiles of serum levels of CITP:MMP-1 ratio using a univariate analysis of variance (ANOVA) model with repeated measurements.
Values are expressed as mean ± standard deviation and median [interquartile range (IQR)] for continuous variables, and as numbers and percentages for categorical variables. A P-value ≤0.05 was considered statistically significant, and all statistical tests were two-sided. The statistical analyses were performed using SPSS (15.0 version) and STATA (12.1 version).
Results
A total of 422 patients were enrolled in the Aldo-DHF trial from March 2007 to April 2011. Of these, 415 had available blood samples and 381 had values of CITP, MMP-1 and PICP at baseline [baseline sample set (BSS); online supplementary Figure S1 ]. In addition, values of PICP and of CITP and MMP-1 were available at 12 months in 370 patients [follow-up sample set (FSS); online supplementary Figure S1 ].
Analyses at baseline
In the BSS, the distribution of serum CITP:MMP-1, as a marker of collagen cross-linking, departed from normality and was positively skewed (P < 0.0001). The median of serum CITP:MMP-1 was 3.91 (IQR 1.86-6.68). Patients were categorized at baseline according to tertiles of increasing serum CITP:MMP-1 ratio levels. Diastolic and mean blood pressure increased across CITP:MMP-1 tertiles probably due to a decreasing percentage of patients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers along the tertiles ( Table 1) . Of interest, patients showed better diastolic function (i.e. lower E:e' ratio) and improved parameters of exercise capacity [i.e. lower minute ventilation to carbon dioxide production (VE/VCO 2 ) slope and higher maximum exercise duration and Borg score] with increasing CITP:MMP-1 values ( Table 2) . Although weak, a continuous inverse association was found between CITP:MMP-1 ratio and E:e' ratio, not reaching statistical significance after adjustment for confounders (online supplementary Table S1 ). In addition, a direct continuous significant correlation was found between CITP:MMP-1 ratio and the Borg score, independently of confounders (online supplementary Table S1 ).
In all patients, the distribution of serum PICP, as a marker of collagen deposition, departed from normality and was positively . Tables S2 and S3 ). Sodium levels were greater with higher PICP values (online supplementary Table S2 ). Left atrial volume index, E-wave velocity and NT-proBNP increased across tertiles of PICP (online supplementary Table S3 ). Continuous direct associations were found between PICP and left atrial volume index and NT-proBNP, independently of confounders in models 2 and 3 (online supplementary Table S1 ).
Analyses after 12 months of treatment Whole cohort
Over the course of 12 months, treatment with spironolactone showed similar effects in the subgroup of patients included in the FSS, as in those reported in the original Aldo-DHF study 15 (online supplementary Table S4 ). Levels of serum PICP decreased (P = 0.050) after 12 months of treatment with spironolactone compared with placebo (online supplementary Table S4 and Figure  S2A ). The serum CITP:MMP-1 ratio remained unchanged after 12 months of treatment (online supplementary Table S4 and Figure  S2B ). A weak correlation was found between changes in E:e' ratio and changes in serum PICP in all patients in the FSS set (r = 0.111, P = 0.033) (online supplementary Figure S2C ) that remained statistically significant after adjustment for confounders in model 2 (P = 0.028) but did not reach statistical significance after full adjustment in model 3 (P = 0.065). In addition, changes in serum PICP were directly correlated with changes in serum NT-proBNP (r = 0.146, P = 0.005) (online supplementary Figure S2D ), independently of confounders in models 2 and 3 (P ≤ 0.022).
Analyses by tertiles
Tests for interaction to globally assess the heterogeneity of treatment effects on E:e' ratio among tertiles of the baseline variables CITP:MMP-1 and PICP have been performed. A significant interaction was detected between CITP:MMP-1 tertiles and the effect of spironolactone on E:e' ratio (P = 0.014). Further analyses adjusting for age and prevalence of coronary artery disease at baseline confirmed this interaction. No significant interaction was detected when categorization was based on PICP tertiles. Once the heterogeneity of treatment was confirmed for the CITP:MMP-1-based categorization, we analysed treatment effects within each one of the CITP:MMP-1 tertiles. At baseline, no differences were found in demographic, clinical and biochemical parameters between patients treated with spironolactone or placebo, in any of the CITP:MMP-1 tertile-based subgroups (online supplementary Tables S5 and S6). After 12 months of treatment, spironolactone did not modify E:e' ratio in patients with low CITP:MMP-1 ratio levels (1st tertile; Figure 1A and Table 3 ), but was associated with a significant decrease in E:e' ratio in patients with medium or high CITP:MMP-1 ratio values (2nd and 3rd tertiles; Figure 1B and 1C, respectively) as compared with placebo. In patients with low levels of the CITP:MMP-1 ratio, the Values are expressed as mean ± standard deviation and categorical variables as number (%). ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blockers; BMI, body mass index; CITP, carboxy-terminal telopeptide of collagen type I; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HR, heart rate; MAP, mean arterial pressure; MMP-1, matrix metalloproteinase-1; NYHA, New York Heart Association; SBP, systolic blood pressure.
circulating levels of PICP were unchanged with spironolactone ( Figure 2A) , whereas in patients with medium or high CITP:MMP-1 ratio values, the decline in E:e' was accompanied by a reduction in the circulating levels of PICP as compared with baseline (2nd and 3rd tertiles; Figure 2B with treatment, whereas placebo-treated patients did show similar peptide levels at the end of treatment as compared with baseline (online supplementary Figure S3 ). No effects of treatment on NT-proBNP circulating levels were observed in the remaining patients (online supplementary Figure S3 ). In Aldo-DHF, a slight reduction in 6-minute walk distance after 1-year treatment with spironolactone vs. placebo was observed. Interestingly, this decline in exercise capacity was detectable in those patients with a low CITP:MMP-1 ratio ( Table 3) .
Discussion
The main findings of this study are the following: (i) in HFpEF patients, spironolactone therapy reduced serum levels of the biomarker of collagen deposition, PICP, but did not modify the serum levels of the biomarker of collagen cross-linking, the CITP:MMP-1 ratio; (ii) spironolactone did not improve diastolic function in the subset of patients with lower CITP:MMP-1 ratio (i.e. a higher degree of collagen cross-linking); and (iii) spironolactone did not reduce serum levels of PICP in the subset of patients with lower CITP:MMP-1 ratio. To our knowledge, this is the first study analysing the effects of spironolactone on the quantity and quality of the myocardial collagen network, as assessed non-invasively . using circulating biomarkers that exhibit histologically proven associations with these characteristics of collagen tissue, in patients with HFpEF. In addition, to the best of our knowledge, this is the first time that the impact of the characteristics of myocardial fibrosis on the effects of spironolactone on LV diastolic function has been evaluated. We observed that, at baseline, HFpEF patients with low serum levels of CITP:MMP-1 ratio exhibit higher E:e' ratio. These findings support previous clinical evidences of an association between myocardial collagen cross-linking and increased LV filling pressures in patients with HF 20 and specifically in patients with HFpEF.
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In addition, we describe for the first time that low levels of CITP:MMP-1 ratio associate with parameters reflecting worse cardiopulmonary exercise performance. On the other hand, we found that PICP directly associates with NT-proBNP and left atrial volume index, in HFpEF patients at baseline. In this regard, associations of PICP with NT-proBNP and left atrial size have been previously reported in HF patients with reduced ejection fraction. 21, 22 Overall, the observations at baseline suggest that myocardial fibrosis, considering its qualitative and quantitative aspects, is related to LVDD and lower exercise performance in patients with HFpEF.
Previous clinical studies demonstrate that spironolactone reduces the circulating serum levels of PICP in asymptomatic patients with LVDD. 23 This study reports for the first time that spironolactone treatment is associated with a reduction in serum PICP in patients with HFpEF. In addition, we observed that treatment with spironolactone is not able to modify the serum levels of CITP:MMP-1 in these patients. Therefore, spironolactone seems capable of affecting the myocardial collagen content but unable to modify the characteristics of the collagen fibre that determine its insolubility, stiffness and resistance to degradation. Experimental studies demonstrate that aldosterone increases the expression of lysyl oxidase 24 -26 (the myocardial enzyme responsible for collagen cross-linking) and the tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), 27 indicating that this hormone may also contribute to myocardial fibrosis by incrementing the stability of the collagen fibre. In this regard, it is plausible that incomplete mineralocorticoid receptor blockade with spironolactone in the myocardium might still allow for aldosterone-or another pro-fibrotic molecule-induced collagen cross-linking and deposi- receptor blockage at the myocardial level may be able to inhibit aldosterone actions with sufficient efficacy to influence the quantitative and qualitative characteristics of the myocardial collagen network. These possibilities are speculative and further studies are necessary to fully clarify these aspects. Interestingly, we have observed that spironolactone did not improve LV diastolic function and failed to reduce collagen deposition (as assessed by serum PICP) in patients exhibiting lower CITP:MMP-1 serum levels, or in other words, higher collagen cross-linking, at baseline (Figure 3) . Given that the degree of cross-linking is associated with high filling pressures in HFpEF patients, 10 it is tempting to speculate that the incapacity of spironolactone to improve LV diastolic function in patients with high cross-linking may be related to its inability to affect the stability of the collagen fibre. Therefore, these results suggest that spironolactone could be a more successful treatment in HFpEF patients with a phenotype indicative of a non-excessive degree of collagen cross-linking, in which a higher efficacy to modulate collagen metabolism and improve LV function may be achieved.
In the Aldo-DHF original study, 15 spironolactone was associated with a subtle reduction in submaximal exercise capacity. Interestingly, the current subanalysis reveals that only in patients with high collagen cross-linking, exhibiting symptoms of altered cardiopulmonary exercise performance at baseline, spironolactone treatment is associated with a reduction in 6-minute walk distance. In this regard, we may speculate that those Placebo (n=59) *  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . patients with high collagen cross-linking exhibiting resistance to spironolactone-induced improvement of LV diastolic function may be more susceptible to treatment side effects of the drug on submaximal exercise capacity. Of interest, some evidence suggests that other therapeutic options are able to target the excess of collagen cross-linking in the myocardium. For instance, the loop diuretic torasemide is associated with significant reductions in both the severity of the deposition of collagen type I fibres and the degree of myocardial collagen cross-linking, as well as with significant improvement of LV function and NYHA functional class in patients with HF. 13, 28 None of these effects were observed in furosemide-treated HF patients. 13, 28 In addition, the losartan metabolite EXP3179 prevents excessive myocardial collagen cross-linking, among other anti-fibrotic actions, in a model of experimental hypertension. 29 Collectively, these findings allow us to suggest further clinical designs to investigate whether these compounds may be optional drugs to complement therapeutic strategies for the personalized treatment of HFpEF patients with a biochemical phenotype indicative of excessive collagen cross-linking.
Some limitations need to be acknowledged. First, this is a post-hoc analysis re-evaluating the Aldo-DHF clinical trial by subgroups. Clinical trial subanalyses are prone to false negative results since they may be inadequately powered to uncover treatment effect differences, even in the presence of true treatment effect modification. Nonetheless, these analyses revealed significant . treatment effect differences in subgroups exhibiting similar sample size. Second, the reduction in sample size due to CITP:MMP-1 tertile categorization may have affected the statistical power to detect significant differences in between-subject analyses comparing spironolactone vs. placebo effects on the biomarkers PICP and NT-proBNP. Nonetheless, the less conservative within-subject comparisons did detect significant effects of spironolactone on these biomarkers. Third, covariates unaccounted for in the analyses and potential problems related to multiplicity could have influenced the findings obtained. Fourth, these findings have not been validated in an independent cohort. Therefore, we believe that the results showing the impact of collagen cross-linking on the spironolactone effects on LV dysfunction and collagen deposition should be hypothesis-generating and need to be confirmed in larger prospectively designed studies.
In conclusion, this study shows for the first time that spironolactone is unable to modify the circulating levels of a biomarker of myocardial collagen cross-linking, the CITP:MMP-1 ratio, in HFpEF patients. In addition, we describe for the first time that patients with low serum levels of this biomarker before treatment, indicative of a high degree of myocardial collagen cross-linking, do not respond to spironolactone in terms of LV diastolic function improvement and reduction of myocardial collagen content (Figure 3) . On the whole, these data suggest that the ability of spironolactone to reduce myocardial fibrosis and improve LV diastolic function is determined by the stability of the collagen fibre in HFpEF patients. These findings support the notion that a Figure 3 Diagrammatic representation of spironolactone effects in patients with low or high levels of myocardial collagen cross-linking, as assessed by high or low circulating values of the carboxy-terminal telopeptide of collagen type I to the matrix metalloproteinase-1 (CITP:MMP-1) ratio, respectively. In the process of degradation of the collagen type I fibre within the myocardial interstitium, MMP-1 cleaves a small C-terminal telopeptide or CITP. A higher degree of cross-linking between collagen type I fibrils increases their resistance to degradation by MMP-1, generating a lower amount of CITP. Both MMP-1 and CITP reach the systemic circulation and thus can be measured by specific enzyme-linked immunosorbent assay methods. Only in patients with a high CITP:MMP-1 ratio, indicative of a low collagen cross-linking and therefore a lower resistance of the collagen type I fibre to degradation, treatment with spironolactone is able to reduce myocardial collagen content (as assessed by the biomarker of myocardial collagen content carboxy-terminal propeptide of procollagen type I or PICP), and improves diastolic function (as assessed by the E:e' ratio). LV, left ventricular. precise biomarker-based phenotyping of patients with HFpEF is critical to advance in the field of HFpEF therapy.
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